Experiment Study On The Biologic Response Of ～(131)I-Rituximab To B Cell Lymphoma Cells

Objectives1. To test the cytotoxicity with ¹³¹I-Rituximab to the the CD20-positive human B-lymphoma cell, and evaluate whether it could induce apoptosis in B-lymphoma cells and study the possible killing mechanisms of ¹³¹I-Rituximab.2. To compare the cytotoxicity of ¹³¹I-Rituximab with the single ¹³¹I or Rituximab to the CD20-positive human B-lymphoma cell, and evaluate the anticancer activity of ¹³¹I-Rituximab to human B-lymphoma.3. To guide the afterward animal and clinical trials and clinical therapy for the use of ¹³¹I-Rituximab to the treatment of relapsed or refractory non-Hodgkin's B-cell lymphoma and offer more extensive and exact experiment fundament and theory evidence.Materials and methods1. CD20-positive human Burkitt's lymphoma cell lines Ramos(RA-l) cell and Raji cell as the testing cell and CD20-negative T lymphoma cell lines Molt-4 cell as the control cell were studied. The growth curve was tested and CD20 expression rates of the three cells in the exponential growth phase was measured by flow cytometric analysis.2. The binding inhibition ratio of Rituximab was measured by flow cytometric...